Two Bets on Complex Molecules, One Asset Light Model
Peptides and high potency APIs are hard to make and even harder to source. That is exactly what makes them valuable, and it is where HRV Pharma is putting its next ₹150 crore.
A Dedicated Peptide Programme
Rediff Money covered the two part plan. The first is a ₹40 to 50 crore peptide programme, with HRV underwriting dedicated partner capacity instead of building its own, while keeping the IP, the regulatory assets and the commercial rights.
Joint Venture for High Potency APIs
The second is a joint venture of around ₹100 crore focused on high potency oncology APIs and specialised molecules, with 20 to 30 products planned in phases for the US, Europe and other regulated markets.
One Asset-Light Business Model
Both follow the same thinking that built HRV in the first place. Own the filings, the IP and the customer, and let specialist partners do the manufacturing
Featured in Rediff Money
Read the full article on Rediff Money
https://money.rediff.com/news/market/hrv-pharma-invests-150-cr-in-peptides-high-potent-apis/53902120260907
